half-life is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-02-13. Where a claim depends on a specific study, the study is described rather than over-claimed.
The distinction between established facts and open questions matters here. That the peptide binds the GLP-1 receptor and stimulates insulin release in a glucose-dependent manner is well documented. How individual variability in receptor density, gastric emptying rate, and gut microbiome composition shapes response remains an active research area. Long-term outcomes beyond five years of continuous use are not yet fully characterized in published trials, and several extension studies are ongoing.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L cells after food intake. The molecule is a 31-amino-acid backbone modified at three positions to resist cleavage by dipeptidyl peptidase-4, the enzyme that degrades native GLP-1 within minutes. A lysine residue at position 26 carries a linker and a C18 fatty diacid, which promotes binding to serum albumin and slows renal clearance. These changes extend the circulating half-life from roughly two minutes to about one week in humans.
The sequence incorporates alpha-aminoisobutyric acid at position 8, replacing the alanine found in the natural hormone. This substitution blocks the primary DPP-4 recognition site and contributes most of the enzymatic stability. Albumin binding further protects the peptide and reduces the frequency of administration required to maintain active plasma levels. Because the fatty acid chain increases lipophilicity, the compound is formulated as a solution rather than a simple aqueous buffer. Researchers describe the design as an incremental optimization of earlier GLP-1 analogs rather than a wholly new scaffold.
Clinical studies of semaglutide generally measure glycated hemoglobin, fasting plasma glucose, body weight, and composite cardiovascular endpoints. The SUSTAIN program enrolled adults with type 2 diabetes, while the STEP program focused on obesity without diabetes. Administration follows a stepwise escalation schedule designed to limit gastrointestinal effects during the first weeks. Reported outcomes include mean percentage weight change, the proportion of participants reaching defined weight-loss thresholds, and rates of nausea, vomiting, and diarrhea. Long-term data on durability after treatment stops are still limited and remain a topic of ongoing research.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, developed by Novo Nordisk and first approved in 2017 for type 2 diabetes. It belongs to the incretin mimetic class, a group of agents that reproduce the glucose-dependent actions of endogenous GLP-1. The molecule was engineered to resist degradation by dipeptidyl peptidase-4 and to bind serum albumin, extending its half-life from minutes to roughly one week. Approval for chronic weight management followed in 2021, based on large cardiovascular and obesity outcome trials.
GLP-1 receptors are expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises cyclic AMP, enhances glucose-dependent insulin secretion, and suppresses glucagon release when blood glucose is high. Effects on gastric emptying and on hypothalamic appetite circuits reduce energy intake. Because insulin release remains glucose-dependent, the risk of hypoglycemia is low when the drug is used alone. The precise contribution of each pathway to body weight change in humans remains an area of active investigation.
| Property | Value | Notes |
|---|---|---|
| Molecular formula (free base) | C187H291N45O59 | Approximate; salt and hydrate forms differ |
| Molecular weight | ~4113.6 Da | Varies with counterion and hydration |
| Appearance | White to off-white powder | Lyophilized research material |
| Solubility class | Freely soluble in water | As formulated; native peptide less stable near neutral pH |
| Typical storage | 2 to 8 degrees Celsius | Protect from light; avoid repeated freeze-thaw |
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
Routine characterisation of the peptide relies on reversed-phase high-performance liquid chromatography, often paired with ultraviolet detection near 214 nanometres. Related substances such as deamidated, oxidised, and truncated sequences elute at characteristic positions and are quantified by area percentage. Electrospray ionisation mass spectrometry confirms the molecular mass and can resolve some closely related variants. Peptide mapping after enzymatic digestion provides sequence-level verification and is useful when a full identity profile is required. Method parameters such as column chemistry, gradient, and mobile-phase pH influence the separation and must be reported alongside results.
Material described as research-grade is not necessarily manufactured to pharmaceutical standards, and purity figures depend on the method used to obtain them. A certificate of analysis states the measured purity, the analytical technique, and the batch identifier, but the underlying data are not always included. Independent testing by a second laboratory is a common way to confirm identity and purity. Uncertainties remain about how storage history affects long-term stability, and about how well results from one laboratory transfer to another. Documentation of handling conditions supports comparison between batches.
Peptides are sensitive to temperature, light, oxygen, and repeated freeze-thaw cycles. Semaglutide in dry form is generally held at refrigerated temperatures, while reconstituted solutions require a defined short-term storage window. Vials should be kept in secondary packaging to limit photodegradation, and exposure to alkaline conditions is avoided because it accelerates chemical degradation. Adsorption to glass and some plastics can reduce the measured concentration of dilute solutions, so low-binding polypropylene containers are preferred for analytical work. Each transfer step introduces a small risk of contamination, and closed handling practices reduce that risk.
Lyophilized semaglutide is typically stored at temperatures between minus 20 and minus 80 degrees Celsius for long-term preservation. Short-term storage at 2 to 8 degrees Celsius is common for working aliquots. Repeated freeze-thaw cycles can degrade the peptide and are usually avoided. The molecule is hygroscopic in its solid form, so containers should remain sealed with desiccant. Solutions are less stable than powders and are generally prepared fresh. Light exposure is limited because aromatic residues can undergo photo-oxidation.
Semaglutide dissolves readily in water and in aqueous buffers near neutral pH. Solubility decreases near the isoelectric point, where net charge is minimal. Common laboratory solvents include phosphate-buffered saline and dilute ammonium bicarbonate. Strongly acidic or basic conditions may accelerate hydrolysis. Working concentrations are usually prepared by diluting a concentrated stock. Vial surfaces can adsorb small amounts of peptide at low concentrations, so carrier proteins or low-binding tubes are sometimes used.
Lyophilised semaglutide is generally held at -20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept at 2-8 °C and used within a defined window because degradation accumulates over time. Repeated freeze-thaw cycles are discouraged, since each cycle can promote aggregation and reduce monomeric content. Room-temperature stability of the solid has been examined in some studies but remains incompletely characterised for long durations, so cold storage is the conservative default for research material.
Degradation proceeds along several parallel routes. Deamidation of asparagine and glutamine residues generates charged variants that shift retention time in chromatographic analysis. Oxidation targets methionine and can be accelerated by trace metals or dissolved oxygen. Non-covalent aggregation produces dimers, oligomers, and larger species that are difficult to reverse. Isomerisation at aspartate residues is slower but measurable under thermal stress. The distribution among these pathways depends on pH, buffer composition, ionic strength, and the presence of excipients such as sugars or surfactants.
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 nm is the standard purity method, reported as area percent. Mass spectrometry, usually with electrospray ionisation, confirms identity and reveals covalent modifications. Size-exclusion chromatography quantifies aggregates and fragments. Peptide mapping after enzymatic digestion localises changes to specific sequence regions. Circular dichroism and infrared spectroscopy report on secondary structure, while light scattering tracks particle formation in liquid formulations. No single technique captures every quality attribute.
=== Foundation: 1977 === On 2 March 1977, the General People's Congress adopted the "Declaration on the Establishment of the Authority of the People" at Gaddafi's behest. Dissolving the Libyan Arab Republic, it was replaced by the Great Socialist People's Libyan Arab Jamahiriya (Arabic: الجماهيرية العربية الليبية الشعبية الاشتراكية, al-Jamāhīrīyah al-‘Arabīyah al-Lībīyah ash-Sha‘bīyah al-Ishtirākīyah), a "state of the masses" conceptualized by Gaddafi. A new, all-green banner was adopted as the country's flag. Officially, the Jamahiriya was a direct democracy in which the people ruled themselves through the 187 Basic People's Congresses (BPCs), where all adult Libyans participated and voted on national decisions. These then sent members to the annual General People's Congress, which was broadcast live on television. In principle, the People's Congresses were Libya's highest authority, with major decisions proposed by government officials or with Gaddafi himself requiring the consent of the People's Congresses. Gaddafi became General Secretary of the GPC, although he stepped down from this position in early 1979 and appointed himself "Leader of the Revolution".
=== Trial and conviction === On May 10, 2010, a three-week trial commenced where Second Circuit District judge John F. Keenan presided. The trial concluded on June 4 when the jury returned a guilty verdict on all five counts, albeit, guilty on a lesser charge of aiding and abetting rather than running a sanctions violation money transmittal system. On June 7, 2010, despite the superseding indictment charge of $3.4 million, the same jury agreed to forfeit one bank account associated with a $6,000 transaction as the proceeds of the charges and the guilty verdict. The jury ruled that Mahmoud Reza Banki's other assets including the apartment he had purchased with the family funds he had received was not a direct proceeds of any crime and not forfeitable. Judge Keenan overruled the jury only in the case of the forfeiture verdict on the basis that the jury might have been "confused" and awarded the government prosecutors a money judgment order, essentially ignoring the jury verdict on forfeiture and awarding the US Attorney's office $3.4 million, to be paid by Banki. This would have been the same as if the jury had come to the decision of full forfeiture of all of Banki's assets.
A familial form of pseudohyperkalemia, a benign condition characterised by increased serum potassium in whole blood stored at cold temperatures, also exists. This is due to increased potassium permeability in red blood cells.
== Research == Ogston studied potentiometric titration of amino acids in non-aqueous solvents. He was particularly interested in sinovial fluid, and fibrous proteins. More generally, he worked on the use of physico-chemical methods to study the size, weight, and structure of molecules, such as ultracentrifugation, which he applied to insulin, for example, and electrophoresis. In this context he made many improvement to equipment used for studying the physical chemistry of proteins. For example, he devised a novel type of apparatus for measuring viscosity. He made many studies of enzymes such as peroxidase and creatine phosphotransferase. He contributed to the general field of enzyme kinetics by studying activation and inhibition. He made a sceptical study of the suggestions of a repetitive structure of proteins made by Bergmann and Niemann and by Wrinch that were widely discussed in the 1940s.
== Structure == There are three types of muscle tissue in vertebrates: skeletal, cardiac, and smooth. Skeletal and cardiac muscle are types of striated muscle tissue. Smooth muscle is non-striated. There are three types of muscle tissue in invertebrates that are based on their pattern of striation: transversely striated, obliquely striated, and smooth muscle. In arthropods there is no smooth muscle. The transversely striated type is the most similar to the skeletal muscle in vertebrates. Vertebrate skeletal muscle tissue is an elongated, striated muscle tissue, with the fibres ranging from a few millimeters to several inches in length and from 10 to 100 micrometers in width. Skeletal striated muscle tissue is arranged in regular, parallel bundles of myofibrils, which contain many contractile units known as sarcomeres, which give the tissue its striated (striped) appearance. Skeletal muscle is voluntary muscle, anchored by tendons or sometimes by aponeuroses to bones, and is used to affect skeletal movement such as locomotion and to maintain posture. Postural control is generally maintained as an unconscious reflex, but the responsible muscles can also react to conscious control. The body mass of an average adult man is made up of 42% of skeletal muscle, and an average adult woman is made up of 36%. Cardiac muscle tissue is found only in the walls of the heart as myocardium, and it is an involuntary muscle controlled by the autonomic nervous system. Cardiac muscle tissue is striated like skeletal muscle, containing sarcomeres in highly regular arrangements of bundles.
Sources: en.wikipedia.org
=== Other === Chest pain may be accompanied by sweating, nausea or vomiting, and fainting, and these symptoms may also occur without any pain at all. Dizziness or lightheadedness is common and occurs due to reduction in oxygen and blood to the brain. In females, the most common symptoms of myocardial infarction include shortness of breath, weakness, and fatigue. Females are more likely to have unusual or unexplained tiredness and nausea or vomiting as symptoms. Females having heart attacks are more likely to have palpitations, back pain, labored breath, vomiting, and left arm pain than males, although the studies showing these differences had high variability. Females are less likely to report chest pain during a heart attack and more likely to report nausea, jaw pain, neck pain, cough, and fatigue, although these findings are inconsistent across studies. Females with heart attacks also had more indigestion, dizziness, loss of appetite, and loss of consciousness. Shortness of breath is a common, and sometimes the only symptom, occurring when damage to the heart limits the output of the left ventricle, with breathlessness arising either from low oxygen in the blood or pulmonary edema. Other less common symptoms include weakness, light-headedness, palpitations, and abnormalities in heart rate or blood pressure. These symptoms are likely induced by a massive surge of catecholamines from the sympathetic nervous system, which occurs in response to pain and, where present, low blood pressure.
John Cowan – bass, lead and backing vocals (1993–1995, 2010–present) Marc Russo – saxophones (1998–present) Ed Toth – drums, percussion (2005–present) Marc Quiñones – percussion, backing vocals (2018–present)
=== Breastfeeding === Paracetamol is excreted in breast milk at measurable concentrations (milk/plasma ratio approximately 1), but the amount ingested by the infant is much lower than paediatric therapeutic doses and rarely associated with clinical effects. Use during breastfeeding is considered compatible at recommended doses, with extra caution for preterm infants or infants with liver disease.
A regulatory enzyme is an enzyme in a biochemical pathway which, through its responses to the presence of certain other biomolecules, regulates the pathway activity. This is usually done for pathways whose products may be needed in different amounts at different times, such as hormone production. Regulatory enzymes exist at high concentrations (low Vmax) so their activity can be increased or decreased with changes in substrate concentrations
=== Singles === "Life" (1999) "Believer" (1999) "Too Late Tonight" (1999) "Me And My Melody" (2000) "All Will Wait" (2000) "You Are" (2002) "Everlasting Change" (2002) "Life On Mars" (2002) "Let Her Down Easy" (2003) "Words" (2007) "Why Do You Run" (2007) "Come On" (2010) "Broken Dancer" (2010) "The High Life" (2011) "Seven Odd Years" (2012)
Sources: en.wikipedia.org
Specimens may also be stored using nested protective packaging systems; one example is the "Swedish method", in which paper envelopes are placed in cardboard boxes and then in larger rigid boxes. The Muséum national d'histoire naturelle has described varied packaging approaches in its collections, including boxes, envelopes, bound herbarium boards, and specialised slide collections for microscopic groups. The general aim of curation is to preserve both the physical structure needed for morphological study and the chemical integrity required for molecular analysis. Drying techniques vary: heat drying at 40–50 °C (104–122 °F) typically favours the retention of microscopic structures, while freeze-drying preserves colour and macroscopic form at the cost of increased fragility. For damp or woody material, low-temperature drying with high ventilation helps prevent further fungal growth and may limit DNA damage. Although liquid preservation in alcohol or formalin maintains a specimen's three-dimensional shape, it often results in colour loss and DNA degradation. While liquid preservation in glass containers maintains a specimen's three-dimensional shape, the choice of preservation method involves trade-offs between physical integrity and the suitability of the material for future DNA analysis. Because many fungi change markedly in appearance during drying, collecting practice has long included recording features of the living fungus through notes and images; the research value of a specimen is increased when such derivative documentation remains linked to the specimen record.
=== Inreda AP === In collaboration with the Academic Medical Center in Amsterdam, Inreda Diabetic B.V. has developed a closed loop system with insulin and glucagon. The initiator, Robin Koops, started to develop the device in 2004 and ran the first tests on himself. In October 2016 Inreda Diabetic B.V. got the ISO 13485 license, a first requirement to produce its artificial pancreas. The product itself is called Inreda AP, and soon made some highly successful trials. After clinical trials, it received the CE marking, noting that it complies with European regulation, in February 2020. In October 2020 the health insurance company Menzis and Inreda Diabetic then started a pilot with 100 patients insured by Menzis. These are all patients that face very serious trouble in regulating their blood glucose levels. They now use the Inreda AP instead of the traditional treatment. Another large scale trial with the Inreda AP was set up in July 2021, and should determine whether Dutch health insurance should cover the device for all their insured. A smaller improved version of the Inreda AP is scheduled for release in 2023.
== In medicine == Prolactin is available commercially for use in other animals, but not in humans. It is used to stimulate lactation in animals. The biological half-life of prolactin in humans is around 15–20 minutes. The D2 receptor is involved in the regulation of prolactin secretion, and agonists of the receptor such as bromocriptine and cabergoline decrease prolactin levels while antagonists of the receptor such as domperidone, metoclopramide, haloperidol, risperidone, and sulpiride increase prolactin levels. D2 receptor antagonists like domperidone, metoclopramide, and sulpiride are used as galactogogues to increase prolactin secretion in the pituitary gland and induce lactation in humans.
==== Anti-inflammatory treatments ==== Topical corticosteroids are effective in short-term treatment of seborrhoeic dermatitis and are as effective or more effective than antifungal treatment with azoles. These are sometimes used for a few weeks at a time. There is also evidence for the effectiveness of topical calcineurin inhibitors like tacrolimus and pimecrolimus as well as lithium salt therapy. Calcineurin inhibitors were also effective in reducing the growth of Malassezia, offering two routes by which they may treat seborrhoeic dermatitis. Medications such as calcineurin inhibitors are not often used in individuals with seborrhoeic dermatitis who are immunocompromised because they cause further immune suppression. Oral immunosuppressive treatment, such as with prednisone, has been used in short courses for seborrhoeic dermatitis, as a last resort due to its potential side effects.
Sources: en.wikipedia.org
It is a modified version of the natural hormone, with three amino acid changes and a fatty acid side chain added. These edits extend its half-life from minutes to about one week. The core receptor activity is retained.
Both deliver the same active peptide and act on the same receptor. The tablet includes an absorption enhancer because peptides are poorly taken up intact from the gut. Bioavailability of the oral route is substantially lower, so the two are not dose-equivalent.
No, it is entirely synthetic and does not occur in nature. Native GLP-1 is produced in the gut and pancreas, but the analog is manufactured by chemical synthesis or recombinant methods. Traces of the analog are not expected in people who never received it.
It is given either as a once-weekly subcutaneous injection or as an oral tablet taken once daily. The two forms use different absorption strategies, so they are not interchangeable on a milligram-for-milligram basis.